Recipharm Enters Long-Term Supply Agreement with Tillotts Pharma AG
The agreement comprises technology transfer and commercial manufacturing of Tillotts’ gastroenterology products.
CDMO Recipharm announced that it has entered into a long-term supply agreement with Tillotts Pharma AG.
This collaboration comprises technology transfer and commercial manufacturing of Tillotts’ gastroenterology products-Entocort and Asacol for the treatment of Crohn’s disease and ulcerative colitis, as well as a total shared investment of EUR3.5 million (approximately $3.92 million) across Recipharm’s network for this business.
Recipharm will also be involved in the commercial-scale development of Tillotts’ ulcerative colitis drug TP05, which is undergoing clinical evaluation.
Recipharm will provide advanced pellet coating technology for controlled release from its facility in Pessac, France, tablet and capsule manufacturing including final packaging from its facility in Fontaine, France, and bottle filling from its site in Lisbon, Portugal. This agreement is part of Recipharm’s strategy to provide full-service offering to its customers.
Source: Recipharm
Drug Solutions Podcast: A Closer Look at mRNA in Oncology and Vaccines
April 30th 2024In this episode fo the Drug Solutions Podcast, etherna’s vice-president of Technology and Innovation, Stefaan De Koker, discusses the merits and challenges of using mRNA as the foundation for therapeutics in oncology as well as for vaccines.
Drug Shortages and Complying with FDA’s 21 CFR 211.110 Guidance
April 2nd 2025Susan J. Schniepp, distinguished fellow at Regulatory Compliance Associates, and Rona LeBlanc-Rivera, PhD, principal consultant, Regulatory Affairs at Regulatory Compliance Associates, answer some questions about FDA’s January 2025 21 CFR 211.110 guidance document.
